$3.30
Manufacturer: Ukraine
In combination with 3-4 other anti-TB drugs − for the treatment of active tuberculosis of all forms and localities; as monotherapy − for the treatment of latent tuberculosis infection and prevention of tuberculosis in persons who have been or are in close contact with tuberculosis patients.
Description
Izoniazid solution Composition
active substance: isoniazid;
1 ml of solution contains 100 mg isoniazid;
excipient: water for injection.
Izoniazid solution Dosage form.
Injection.
Basic physical and chemical properties: transparent colorless or slightly colored liquid.
Pharmacotherapeutic group. Anti-tuberculosis drugs. ATX code J04A C01.
Izoniazid solution Pharmacological properties
Pharmacodynamics
Isoniazid inhibits DNA-dependent RNA polymerase and inhibits the synthesis of mycolic acids in the cell wall of Mycobacterium tuberculosis. The drug has a high bacteriostatic activity against mycobacterium tuberculosis, delaying their growth at a concentration of 0.03 μg / ml. It is especially active against rapidly multiplying microorganisms. Weakly affects the causative agents of other infectious diseases.
Pharmacokinetics
When administered parenterally, it quickly penetrates into body tissues, biological fluids. Passes through the blood-brain barrier, especially with inflammation of the meninges. Penetrates bones. It is metabolized in the liver, depending on the genetic characteristics of a person, at a higher or lower rate. It is excreted by the kidneys. The half-life in people with a higher metabolic rate of isoniazid is 0.5-1.5 hours, with a lower one – 4-6 hours. It is excreted mainly in the bile, 30% of the dose is excreted in the urine.
Clinical characteristics
Indications
Treatment of all forms and localizations of active tuberculosis in adults and children (as a first-line remedy).
Contraindications
Hypersensitivity to isoniazid or to drug excipients.
Epilepsy and other diseases accompanied by a tendency to convulsive seizures, severe psychosis, poliomyelitis (including history), history of toxic hepatitis due to the use of isonicotinic acid hydrazide derivatives (ftivazide), severe atherosclerosis, acute liver and / or renal failure.
The use of isoniazid at a dose higher than 10 mg / kg of body weight per day is contraindicated during pregnancy, with cardiopulmonary insufficiency, arterial hypertension II-III degree, coronary heart disease, diseases of the nervous system, bronchial asthma, chronic renal failure, hepatitis in the acute phase , cirrhosis of the liver, psoriasis, eczema in the acute phase, hypothyroidism, myxedema.
Recent Reviews